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ABSTRACT
CYLD  negatively  regulates  the  NF-κB  signaling  pathway  and  osteoclast 
differentiation largely through antagonizing TNF receptor-associated factor (TRAF)-
mediated K63-linkage polyubiquitination in osteoclast precursor cells. CYLD activity 
is controlled by IκB kinase (IKK), but the molecular mechanism(s) governing CYLD 
protein stability remains largely undefined. Here, we report that SCFβ-TRCP regulates the 
ubiquitination and degradation of CYLD, a process dependent on prior phosphorylation 
of CYLD at Ser432/Ser436 by IKK. Furthermore, depletion of β-TRCP induced CYLD 
accumulation and TRAF6 deubiquitination in osteoclast precursor cells, leading to 
suppression of RANKL-induced osteoclast differentiation. Therefore, these data 
pinpoint the IKK/β-TRCP/CYLD signaling pathway as an important modulator of 
osteoclastogenesis.
INTRODUCTION
Bone is consistently renewed throughout life by 
the opposing activities of osteoblastic bone formation 
and osteoclastic bone resorption pathways. Although 
osteoclasts are required for bone remodeling, excess 
activity of osteoclasts can lead to various diseases 
such as periodontal disease, osteoporosis, rheumatoid 
arthritis, multiple myeloma and metastatic cancers [1-7]. 
Osteoclasts are largely generated from differentiating bone 
marrow precursor cells, a process that is tightly regulated 
by  various  osteoclast  specific  factors.  Importantly, 
as expressions of these key osteoclast regulators are 
controlled by the NF-κB signaling pathway, elucidating 
how  NF-κB  signaling  is  fine  tuned  during  osteoclast 
differentiation has drawn increased research attention. 
To  this  end,  the  identification  of  osteoprotegerin  and 
receptor activator nuclear factor-κB ligand (RANKL) as 
the dominant mediators of osteoclastogenesis has been a 
major advancement in our understanding of the osteoclast 
differentiation process [8]. Notably, RANKL specifically 
and potently activates nuclear factor of activated T cells 
cytoplasmic 1 (NFATc1), a key transcription factor for 
osteoclastogenesis and the master regulator of osteoclast 
differentiation, via targeting both the TRAF6/NF-κB and 
c-fos signaling pathways [9-13].
SCF (Skp1-Cullin1-F-box protein) E3 ligases are 
well studied Cullin-based E3 ligases, containing a holo-
enzyme composed of three static subunits, namely Skp1 
(S-phase kinase-associated protein-1), Cullin 1 and Rbx1/
Roc 1, as well as a variable F-box protein subunit [14]. To 
date, 69 putative F-box proteins have been identified in the 
human genome, but the substrates and functions of most 
F-box proteins have not yet to be fully characterized [14]. 
The beta-transducin repeat-containing protein (β-TRCP) is 
one of the most well characterized F-box proteins, which Oncotarget 4212 www.impactjournals.com/oncotarget
confers substrate specificity to the SCFβ-TRCP E3 ligase 
complex.  β-TRCP  regulates  diverse  cellular  processes 
largely by promoting degradation of its substrates in a 
phosphorylation-dependent manner [15]. Notably, SCFβ-
TRCP activity has been characterized as a critical positive 
regulator  of  NF-κB  signaling,  both  by  promoting  the 
processing and activation of NF-κB1 and NF-κB2, as 
well as promoting the degradation of IκB, an endogenous 
inhibitor of NF-κB [16, 17]. 
Ubiquitination is a reversible post-translational 
modification  where  E3  ubiquitin  ligases  conjugate 
ubiquitin moieties, either as mono-ubiquitination or 
different  linkage-specific  poly-ubiquitinated  chains,  to 
the targeted substrates. The activities of various ubiquitin 
ligases can be opposed by deubiquitinating enzymes 
(DUBs).  Cylindromatosis  (also  designated  as  CYLD) 
is a well-characterized DUB [18], where mutations in 
CYLD are reported to cause cylindramotosis implicating 
CYLD as a tumor suppressor [19]. Besides suppressing 
tumorigenesis, CYLD has also been found to play critical 
roles in the immune response and bone remodeling 
largely  via  regulating  the  NF-κB  signaling  pathway 
[19-25].  Notably,  multi-layer  regulation  of  the  timely 
activation  of  the  NF-κB  pathway  has  been  shown  to 
be governed by ubiquitin-dependent processes. In this 
regard, while β-TRCP is reported as a positive regulator, 
CYLD is considered largely as a negative regulator of 
the  NF-κB  pathway  by  antagonizing  TRAF-mediated 
K63-linkage  polyubiquitination  of  various  substrates 
[16, 26-28]. Recent studies have demonstrated that under 
diverse  stimulations,  TRAFs-mediated  K63-linkage 
ubiquitination,  as  well  as  LUBAC-dependent  linear-
ubiquitination  of  NEMO  (IKKγ)  [29],  synergistically 
leads to timely activation of NF-κB kinase alpha (IKKα) 
and  IKKβ  to  phosphorylate  the  IκBs.  Subsequently, 
phosphorylated IκBs are degraded by SCFβ-TRCP to induce 
full NF-κB activation. Activated NF-κB in turn promotes 
transcriptional  upregulation  of  CYLD,  leading  to  the 
deubiquitination  and  thereby  deactivation  of  TRAFs, 
functioning as a negative feedback loop between the NF-
κB and CYLD signaling axis [27, 28]. 
Recent studies have suggested that CYLD negatively 
regulates osteoclastogenensis through deubiquitination 
of  TRAF6  [30].  Consistently,  CYLD  deficient  mice 
displayed an osteoporosis phenotype harboring a low 
bone  density.  Moreover,  osteoclast  precursors  derived 
from CYLD deficient mice are more sensitive to RANKL-
induced differentiation [30]. Notably, a mutant (P392L) 
of  p62/SQSTM1,  a  multifunctional  ubiquitin-binding 
protein that is necessary for receptor internalization and 
protein turnover, stimulates differentiation of osteoclast 
in Paget’s disease, a disorder characterized by abnormal 
osteoclastogenensis [31]. Furthermore, mice carrying 
the p62/SQSTM1-P392L mutation show loss of binding 
between CYLD and TRAF6, and loss of deubiquitination 
activity of CYLD towards TRAF6, supporting the critical 
role of CYLD in osteoclast differentiation.
Given the critical role of CYLD in bone remodeling, 
it is important to further understand how CYLD abundance 
is controlled during physiological processes such as 
osteoclast differentiation. However, the identity of the 
upstream E3 ubiquitin ligase responsible for ubiquitinating 
CYLD has remained elusive. Here, we report that β-TRCP 
and IKK are critical mediators controlling CYLD protein 
degradation,  and  β-TRCP  contributes  to  regulating 
osteoclastogenesis through negatively controlling 
CYLD protein stability. Our results further suggest that 
deregulation of the CYLD degradation pathway might 
lead to aberrant bone formation, resulting in bone related 
diseases. 
RESULTS
CYLD interacts with the SCFβ-TRCP E3 ligase 
complex
The stability of multiple critical components of the 
NF-κB pathway is tightly controlled in a proteasome-
dependent manner. Hence, we first examined whether 
CYLD protein stability is also regulated by the ubiquitin-
proteasome pathway. Since proteasome inhibitors, 
including MG132, have been reported to inhibit mRNA 
expression of CYLD and several NF-κB target genes in 
part by elevating the expression of IκB, an endogenous 
inhibitor of NF-κB (Supplementary Figures 1A-G) [27], 
we analyzed how the proteasome inhibitor MG132 might 
affect the abundance of exogenous CYLD. Under ectopic 
expression conditions, the transcription of exogenous 
CYLD mRNA is under control of the CMV promoter. 
Contrary to endogenous CYLD protein levels, we found 
that exogenous CYLD protein was upregulated in MG132 
treated DLD1 cells (Figure 1A). Furthermore, MG132 
treatment extended the half-life of endogenous CYLD 
protein  following  RANKL  stimulation  in  RAW264.7 
mouse macrophage cells, as RANKL stimulation induces 
CYLD mRNA expression, thereby bypassing the down-
regulation of CYLD mRNA expression by MG132 (Figure 
1B). These data suggests that CYLD protein abundance is 
subjected to the regulation by the proteasome degradation 
pathway.
As  Cullin-Ring  type  complex  forms  the  largest 
group of E3 ubiquitin ligases [32], we next tested which 
specific Cullin-Ring E3 ligase might be involved in the 
regulation  of  CYLD  protein  stability.  Using  a  panel 
of  Cullin  members,  we  found  that  exogenous  CYLD 
specifically interacted with Cullin-1, but not other Cullin 
family members (Figure 1C). As Cullin-1 is a scaffolding 
component  of  the  SCF  (Skp1-Cullin1-F-box  protein) 
E3 ligase complex whereby the F-box protein confers 
substrate  specificity,  we  continued  to  explore  which Oncotarget 4213 www.impactjournals.com/oncotarget
F-box protein might interact with CYLD. To this end, 
using a panel of F-box proteins, we identified that CYLD 
specifically interacted with β-TRCP1, but not any of the 
other F-box proteins we tested (Figure 1D). Consistent 
with these observations, using co-immunoprecipitation 
experiments, we detected exogenously expressed CYLD 
associated  with  ectopically  expressed  β-TRCP1  and 
β-TRCP2 (Figure 1E) and endogenous β-TRCP1 (Figure 
1F). Moreover, under extopic co-expression conditions, 
CYLD also interacted with the SCF E3 ligase components 
Skp1 (Figure 1G) and Rbx1 (Figure 1H), suggesting that 
the SCFβ-TRCP E3 ligase complex is involved in regulating 
CYLD protein stability. 
β-TRCP controls CYLD protein stability
To demonstrate that CYLD is a bona-fide substrate 
of SCFβ-TRCP, we next examined whether the interaction of 
β-TRCP with CYLD is through the substrate recognition 
domain of β-TRCP. Utilizing the β-TRCP (R474A) mutant 
that is deficient in binding its substrates for recruitment 
to the SCF complex [33], we observed a significantly 
reduced  ability  of  β-TRCP  (R474A)  to  bind  CYLD 
(Figure 2A), supporting a specific interaction between 
SCFβ-TRCP and CYLD. Furthermore, the observation of 
elevated CYLD protein levels after depleting endogenous 
Figure 1: CYLD interacts with the SCFβ-TRCP E3 ligase complex (A) Immunoblot (IB) analysis of whole cell lysates (WCL) 
derived from DLD1 cells transfected with HA-CYLD with or without MG132 (15 µM) treatment. (B) RAW264.7 mouse 
macrophage cells were treated with RANKL (50 ng/ml) for 24 hours and then treated with or without MG132 (15 µM) for 6 hours prior 
to cycloheximide (CHX) treatment (20 µg/ml). At the indicated time points, WCL were prepared, and IB analysis was performed with the 
indicated antibodies. (C) IB analysis of WCL and anti-HA immunoprecipitates (IP) derived from 293T cells, in which HA-CYLD was co-
transfected with empty vector, Myc-Cullin1, 2, 3, 4A or 5 expression plasmids. (D) IB analysis of WCLs and HA-IP derived from 293 cells 
transfected with HA-CYLD and the indicated GST-tagged F-box proteins. (E) IB analysis of WCL and anti-HA IP derived from 293T cells, 
in which HA-CYLD was co-transfected with Empty vector (EV), Myc-β-TRCP1 or Myc-TRCP2 plasmids as indicated. (F) IB of WCLs 
and anti-HA IP derived from 293T cells transfected with HA-CYLD or EV as a negative control. (G) IB analysis of WCL and anti-Myc IP 
derived from 293T cells transfected with HA-CYLD and Flag-Skp1 as indicated. (H) IB analysis of WCL and anti-Flag IP derived from 
293T cells transfected with HA-CYLD and Flag-Rbx1 as indicated. Oncotarget 4214 www.impactjournals.com/oncotarget
Cullin-1 or β-TRCP by multiple shRNAs suggested that 
CYLD is a potential physiological substrate for SCFβ-
TRCP (Figures 2B-C and Supplementary Figures 2A-C). 
Notably,  depletion  of  endogenous  β-TRCP1  resulted 
in a significant increase in the half-life of CYLD and a 
representative β-TRCP substrate IκBα (Figures 2D-F). 
Taken together, these results indicated that SCFβ-TRCP might 
negatively regulate the protein stability of CYLD.
IKK  promotes  CYLD  ubiquitination  and 
subsequent degradation
Proper phosphorylation of substrates proteins by 
specific kinase(s) is critical for SCFβ-TRCP to recognize its 
substrate(s) for subsequent ubiquitination and degradation 
[15]. Consistent with a critical role of substrate 
phosphorylation for recognition by SCFβ-TRCP, phosphatase 
treatment led to a marked reduction in interaction between 
CYLD  and  SCFβ-TRCP  (Figure  3A).  As  IKK-mediated 
phosphorylation of CYLD has been reported to negatively 
regulate  CYLD  enzymatic  activity  [34],  we  further 
explored whether IKK is also involved in regulating the 
degradation of CYLD by SCFβ-TRCP. Notably, depletion of 
endogenous IKKs by multiple shRNAs against IKKα or 
IKKβ led to an accumulation of CYLD protein in 293T 
cells (Figure 3B). On the contrary, ectopic expression 
of IKK significantly reduced CYLD protein abundance 
in 293T cells ectopically expressing HA-tagged CYLD 
(Figure 3C). These data therefore indicated a possible 
role for IKK in promoting the degradation of CYLD. 
Notably, among the four reported IKK phosphorylation 
sites [34] (S418, S422, S432 and S436) that may create 
two putative β-TRCP binding motifs (Figure 3E), mutating 
both phospho-degrons of CYLD abolished the interaction 
between CYLD and β-TRCP (Figures 3D-E). However, 
mutating putative degron #2, but not degron #1, led to 
a  resistance  to  IKK/  SCFβ-TRCP-mediated degradation 
of CYLD, arguing that Ser432 and Ser436 serve as the 
dominant  phospho-degron  for  CYLD  degradation  by 
SCFβ-TRCP and IKK (Figure 3C). Although this identified 
phospho-degron motif (GSIGHS) within CYLD is not 
consistent with the canonical β-TRCP degron (DSGXXS), 
it does resemble a reported non-canonical degron found 
within  p53  that  also  contains  IKK  phosphorylation 
sites,  and  other  known  β-TRCP  substrates  including 
Figure 2: β-TRCP controls CYLD protein stability (A) IB analysis of WCL and IP derived from 293T cells transfected 
with HA-CYLD and empty vector (EV), wild-type (WT) or R474A mutant β-TRCP1, as indicated. (B) IB analysis of WCL 
derived from 293T cells infected with shRNA constructs against GFP, Cullin1 (three independent lentiviral Cullin1-targeting shRNA 
constructs namely, -A, -B, -C), followed by selection with 1 µg/ml puromycin for 72 hours to eliminate non-infected cells. (C) IB analysis 
of WCL derived from HeLa cells infected with shRNA constructs against GFP, β-TRCP1 (three independent lentiviral β-TRCP1-targeting 
shRNA constructs β-TRCP1-A, β-TRCP1-B, β-TRCP 1-C), β-TRCP2 or β-TRCP1+2 (shRNA against both β-TRCP1 and 2 isoforms), 
followed by selection with 1µg/ml puromycin for 72 hours to eliminate non-infected cells. (D) To measure CYLD protein half-life changes, 
the RAW264.7 cells were infected with the indicated shRNA followed by selection with 1 µg/ml puromycin for 72 hours to eliminate non-
infected cells. Afterwards, cells were split into 6 cm dishes, treated with 100µg/ml cycloheximide (CHX) and harvested at indicated time 
points. WCL were prepared and IB analyses were performed with the indicated antibodies. (E) Quantification of the CYLD band intensities 
in (D). CYLD band intensity was normalized to tubulin, and then normalized to the t = 0 controls. (F) Quantification of the IκBα band 
intensities in (D). IκBα band intensity was normalized to tubulin, and then normalized to the t = 0 controls.Oncotarget 4215 www.impactjournals.com/oncotarget
Figure 3: IKK promotes CYLD ubiquitination and subsequent degradation (A) IB analysis of WCL and IP derived 
from 293T cells transfected with HA-CYLD and Myc-β-TRCP1 constructs. Where indicated, cell lysates were pre-treated with 
λ-phosphatase (λ-ppase) before the IP procedure. (B) IB analysis of WCL and IP derived from 293T cells transfected with shRNA constructs 
against IKKα, or IKKβ.(C) IB analysis of WCL derived from 293T cells transfected with Flag-β-TRCP1, Flag-IKKβ and WT, S418/422A, 
S432/436A, or S418/422/432/436A(4A) mutant CYLD constructs. (D) IB analysis of WCL and IP derived from 293T cells transfected 
with Flag-β-TRCP1 and wild-type (WT), S418/422A, S432/436A, or S418/422/432/436A (4A) mutant CYLD constructs. (E) Schematic 
structure of CYLD protein and alignment of the reported phosphorylation sites by IKK that may be recognized by β-TRCP. The CYLD 
mutants that are used in this study are also indicated. (F) IB analysis of WCL derived from 293T cells treated with 15 µM MG132 or 
untreated control cells. (G) IB analysis of WCL derived from 293T cells infected with lenti-viral shRNA constructs against GFP, β-TRCP1 
(two independent shRNA, -A and -B) or β-TRCP1+2 (shRNA against both β-TRCP1 and 2 isoforms). (H) IB analysis of WCL and IP 
derived from 293T cells transfected with Flag-β-TRCP1, Myc-Ubiquitin, Flag-IKKβ and HA-tagged WT or S432A/S436A mutant CYLD 
constructs as indicated.Oncotarget 4216 www.impactjournals.com/oncotarget
Figure 4: β-TRCP regulates osteoclast differentiation in part through modulating CYLD abundance to influence 
the activation of NF-κB signaling pathway (A) Tartrate resistant acid phosphatase (TRAP) positive multinucleated cells 
differentiated from bone marrow macrophage cells derived from bone marrow cells in the presence of 100 ng/ml RANKL for 
3 days, followed by treatments with DMSO (control), MG132 (10 µM), Bortezomib (1 µM) or Lactacystin (5 μM). (B) TRAP 
positive multinucleated cells in each well of (A) were counted under microscopes. Data represents mean ± SD (n=3, *p<0.001 by Student’s 
t test). (C) IB analysis of WCL derived from bone marrow macrophage cells treated or non-treated with RANKL (100 ng/ml RANKL for 
3 days) in the presence or absence of 10 µM MG132, as indicated. (D) TRAP positive multinucleated cells in the control or β-TRCP1 and 
β-TRCP2 double knockdown bone marrow precursor cell line in the presence of 100 ng/ml RANKL for 12 hours. (E) IB analysis of WCLs 
derived from the control or β-TRCP1+2 knockdown bone marrow precursor line in the presence of 100 ng/ml RANKL for the indicated 
time periods. (F) In vivo ubiquitination assay was performed using RAW264.7 cells infected with shRNA lentiviral vector against GFP, 
β-TRCP1, and β-TRCP1+2 (shRNA against both β-TRCP1 and 2 isoforms) followed by selection with 1 µg/ml puromycin for 72 hours 
to eliminate the non-infected cells. Then cells were stimulated with 20 ng/ml RANKL and harvested for IP. (G-I) RAW cells transfected 
with EV, HA-CYLD-WT, or -4A expression plasmid were treated with 100 ng/ml RANKL for 3 days, and fixed for TRAP staining for 
osteoclasts (G). TRAP positive multinucleated cells were counted. Data shown are the numbers of TRAP positive multinucleated cells per 
well of 96 well cell culture plate. Data represents mean ± SD (n=3, *p<0.05, **p<0.001 by Student’s t test) (H). IB analysis of WCL derived 
from the indicated RAW cells was presented in (I).Oncotarget 4217 www.impactjournals.com/oncotarget
Mcl-1, PHLPP1 and Gli2 (Supplementary Figure 3A) 
[35-38]. To further demonstrate a critical role of the 
phosphorylation  of  Ser432  and  Ser436  in  controlling 
CYLD protein stability, we developed phosphorylation-
specific  antibodies  that  recognize  pSer436-CYLD  or 
pSer432/pSer436-CYLD  (Supplementary  Figures  3B-
C).  Using  these  antibodies,  we  detected  an  elevation 
of  pSer436-CYLD  and  pSer432/pSer436-CYLD  after 
blocking proteasome activity by MG132 (Figure 3F), or 
by depleting endogenous β-TRCP (Figure 3G) in 293T 
cells. These results support the notion that phosphorylation 
of CYLD by IKK at Ser432 and Ser436 is associated with 
β-TRCP-mediated  poly-ubiquitination  and  subsequent 
degradation of CYLD. In further support of this finding, 
mutating Ser432 and Ser436 to Alanine abolished IKK-
dependent,  β-TRCP-mediated  poly-ubiquitination  of 
CYLD in 293T cells (Figure 3H). Together, these results 
demonstrate that IKK-mediated phosphorylation of Ser432 
and Ser436 might play a pivotal role in triggering SCFβ-
TRCP-dependent CYLD poly-ubiquitination.
β-TRCP  regulates  osteoclast  differentiation 
in  part  through  the  β-TRCP/CYLD  signaling 
pathway
Previous  studies  have  identified  that  RANKL 
stimulates osteoclast differentiation through the calcium/
NFAT,  TRAF6/NF-κB  and  c-fos  signaling  pathways 
[9-12]. Given the critical role of TRAF-mediated K63-
ubiquitination as well as the negative feedback role 
of  the  CYLD  deubiquitinase  in  modulating  osteoclast 
differentiation, we decided to examine whether 
proteasome-mediated degradation pathways were 
important  for  RANKL-induced  osteoclastogenesis. 
To this end, we treated bone marrow macrophage 
cells with multiple proteasome inhibitors bortezomib, 
MG132 and lactacystin, and found that RANKL-induced 
osteoclastogenesis was blocked by each of these inhibitors 
(Figures 4A-B). Furthermore, MG132 treatment led to the 
accumulation of CYLD protein under RANKL-stimulated 
condition in which CYLD mRNA level is upregulated 
during  the  RANKL-induced  osteoclast  differentiation 
process with constitutive activation of NF-κB signaling 
(Figure 4C). Notably, elevated CYLD levels in MG132 
treated samples correlate with a reduction of the processed, 
active form, of p52 and elevation of the non-processed 
p100 precursor form of NF-κB2, indicating a suppressive 
effect of NF-κB signaling due to elevated abundance of 
the CYLD DUB. 
On  the  other  hand,  in  the  absence  of  RANKL 
stimulation, there is only basal level activity of NF-κB 
signaling as suggested by the absence of p100 processing 
to active p52. Given that CYLD is a well-characterized 
NF-κB  transcriptional  target,  and  in  keeping  with 
results obtained from DLD1, HCT116 and COS7 cells 
(Supplementary  Figures  1A  and  F-G),  there  are  low 
expression  levels  of  endogenous  CYLD  and  contrary 
to  RANKL-stimulated  conditions,  CYLD  could  not 
be  upregulated  by  MG132  that  is  largely  due  to  the 
inhibitory effects of MG132 towards NF-κB signaling. 
These results indicate that osteoclast differentiation is 
possibly dependent on the proteasome-dependent protein 
degradation pathway that will affect the abundance of 
many key NF-κB regulators including CYLD. Therefore, 
we went on to explore the possible involvement of 
β-TRCP in RANKL-induced osteoclast differentiation. 
To this end, we monitored osteoclast differentiation in 
control and β-TRCP depleted osteoclast precursor cells. 
As shown in Figure 4D, compared to shGFP-infected 
control osteoclast precursor cells, osteoclast differentiation 
induced by RANKL stimulation was significantly blocked 
in β-TRCP depleted cells (Figure 4D). 
In further support of a critical role for CYLD in 
RANKL-mediated  osteoclast  differentiation  process, 
we  found  that  RANKL-dependent  CYLD  degradation 
observed at 0.5, 1, and 3 hours post RANKL stimulation, 
was markedly blocked by knockdown of β-TRCP, and 
likely  due  to  repression  of  IKK  activation  resulting 
from CYLD stabilization (Figure 4E). As CYLD is a 
critical factor that regulates osteoclast activation in part 
through  TRAF6  and  p62/SQSTM1  deubiquitination 
[18]  (Supplementary  Figure  4),  these  results  suggest 
that  β-TRCP  signaling  pathway  may  be  critical  in 
controlling osteoclastogenesis in part by negative 
regulation  of  CYLD  stability  to  influence  the  NF-κB 
signaling  intensity.  In  support  of  this  notion,  in vivo 
poly-ubiquitination assays demonstrate that depletion of 
β-TRCP impaired TRAF6 self-ubiquitination likely due 
to enhancement of TRAF6 deubiquitination by CYLD, 
concomitant  with  a  reduction  in  β-TRCP-dependent 
ubiquitination  of  CYLD  and  impairment  of  auto-
phosphorylation  of  TRAF6-downstream  kinase  IKKα 
(Figure 4F). To further demonstrate that the observed 
suppression of osteoclastogenesis with proteasome 
inhibitors (Figure 4A) or β-TRCP depletion (Figure 4D) 
is partly through CYLD stabilization and elevated CYLD 
activity, we ectopically expressed CYLD-WT or -4A in 
RAW264.7 osteoclast precursor cells, and conducted an 
osteoclastogenesis assay. As shown in Figure 4G-I, ectopic 
expression of both WT and 4A CYLD blocked RANKL-
induced osteocrastgenesis. Importantly, the number of 
differentiated osteoclast cells was significantly lower in 
non-degradable CYLD mutant (CYLD-4A) expressing 
cells  compare  to  CYLD-WT  expressing  cells,  which 
was further confirmed by the western blot analysis of 
the osteocrast marker protein NFATc1. These results 
confirmed previously reported results demonstrating that 
CYLD is a critical negative regulator of osteocrastgenesis 
[25]. Our results further suggest that β-TRCP plays an 
important role in modulating osteoclastgenesis in part 
through promoting ubiquitination-dependent degradation Oncotarget 4218 www.impactjournals.com/oncotarget
of CYLD. Altogether, these results support the model that 
CYLD degradation by SCFβ-TRCP plays a critical role in 
governing the timely activation of the NF-κB signaling 
pathway to control the osteoclast differentiation process 
(Supplementary Figure 4).
DISCUSSION 
Here  we  demonstrated  that  IKK  and  β-TRCP 
negatively  control  CYLD  protein  stability  through 
phosphorylation-dependent  poly-ubiquitination.  Recent 
studies have revealed that various extra-cellular stimuli 
such as RANKL trigger oligomerization and activation 
of the E3 ubiquitin ligase TRAF6 by undergoing K63-
linked self-ubiquitination, which in turn activate the IKK 
complex for timely degradation of IκB that turns on NF-
κB activity (Supplementary Figure 4). On the other hand, 
activated NF-κB stimulates transcriptional upregulation 
of CYLD to antagonize TRAF6 by promoting its K63-
linked deubiquitination, presenting a negative feedback 
loop of NF-κB activation [18]. In our current study, we 
demonstrated that β-TRCP and IKK could possibly sustain 
the activation loop in canonical NF-kB signaling pathway 
in part by downregulating the negative regulator CYLD.
Recent studies have identified important roles of 
the ubiquitin-proteasome system in osteoclastogenesis 
[39]. In keeping with these reports, we found that the 
treatment with multiple proteasome inhibitors such as 
MG132, bortezomib and lactacystin, reduced RANKL-
induced  osteoclast  differentiation  (Figures  4A-B).  In 
accordance with these results, knockdown of β-TRCP 
led to suppression of osteoclast differentiation (Figure 
4D),  suggesting  a  positive  role  of  β-TRCP  during 
osteoclastogenesis.  Depletion  of  β-TRCP  has  been 
shown to have a multiple suppressive effect on NF-κB 
activation including upregulation of IκBα and deficiencies 
in  processing  of  NF-κB1  and  NF-κB2.  Here  we 
demonstrated that during the RANKL-dependent signaling 
pathway, CYLD stabilization by depletion of β-TRCP 
decreased  the  ubiquitination  of  TRAF6  and  impaired 
auto-phosphorylation of the TRAF6-downstream kinase 
IKKα (Figures 4E-F). These results suggest that β-TRCP 
participates in multiple layers to positively control the NF-
κB signaling pathway, in part via governing the stability of 
the CYLD deubiquitinase. 
Studies using knock-out mouse models have 
demonstrated  that  mice  deficient  in  both  NF-κB1 
and  NF-κB2,  but  not  deficient  in  either  one  alone, 
developed osteopetrosis due to defects in osteoclast 
differentiation arguing the involvement of both canonical 
and  non-canonical  NF-κB  signaling  in  this  process 
[40].  Furthermore, TRAF6-deficient  mice  also  exhibit 
defects in the osteoclast differentiation and functions, 
leading to osteopetrosis phenotypes [41]. Consistently, 
CYLD knockout mice displayed an osteolytic phenotype 
associated  with  hyper-ubiquitination  of  TRAF6  and 
persistent activation of its downstream signaling 
molecules including NF-κB and ERK [25]. The sustained 
activation of the NF-κB pathway subsequently leads to 
enhanced sensitization to RANKL stimulation and hyper-
differentiation  of  osteoclast  cells  in  CYLD  deficient 
mice. Interestingly, the point mutation (P392L) of the 
CYLD  interacting  protein  p62/SQSTM1,  an  adaptor 
molecule required for the CYLD-TRAF6-p62/SQSTM1 
complex formation, is reported to predispose individuals 
to the development of Paget’s disease [31]. The primary 
symptoms of this chronic disorder are an enlarged and 
misshapen bone that resembles the reported phenotypes 
of CYLD knockout mice. In this study, we report that 
β-TRCP  depletion  significantly  decreases  TRAF6 
ubiquitination that directs osteoclastogenesis. Thus, 
our findings suggest that dysregulation of the β-TRCP-
CYLD  signaling  pathway  may  contribute  to  various 
bone-related pathogenic phenotypes caused by abnormal 
osteoclastogenesis, and targeting this pathway will be a 
potential strategy to develop new therapeutic intervention 
to treat various osteolytic disorders. The outcomes for 
patients with myeloma have dramatically improved 
over the past decade, largely due to the availability of 
better options for treatment including high-dose therapy, 
thalidomide, bortezomib (Velcade), and lenalidomide [42, 
43]. In some reports, bortezomib treatments have been 
shown to increase bone mineral density in a myeloma/
osteosarcoma mouse model [42, 43]. Our findings will 
further provide new insights into the molecular mechanism 
of how to maintain optimal bone mineral density through 
suppressing the excessive bone resorption process in part 
by inhibiting osteoclast differentiation. 
METHODS
Cell Culture
RAW264.7 mouse leukemic monocyte macrophage 
cell  line  (ATCC,  Manassas,  VA)  was  cultured  in 
alpha-Minimal  Essential  Medium  (αMEM)  medium 
supplemented  with  10%  FBS.  293T,  HeLa,  DLD1, 
HCT116 and COS-7 cell lines were cultured in DMEM 
containing 10% FBS and antibiotics (streptomycin and 
penicillin).
Plasmids
pDest-CYLD-HA  was  obtained  from  Addgene. 
CYLD  and  β-TRCP  mutants  were  generated  with 
QuikChange  XL  Site-Directed  Mutagenesis  kit.  Short 
hairpin RNAs (shRNA) lentiviral pLKO vectors against 
β-TRCP1, β-TRCP2, β-TRCP1+2 and GFP were described 
as previous [44]. Myc-β-TRCP1, Myc-β-TRCP2, Flag-β-
TRCP1 and Flag-β-TRCP1-R474A expression plasmids, Oncotarget 4219 www.impactjournals.com/oncotarget
and  shRNA  lentiviral  vectors  against  Cullin-1  were 
obtained  from  Dr.  J.  Wade  Harper  (Harvard  Medical 
School, Boston, MA.). Myc-Cullin-1, Myc-Cullin-2, Myc-
Cullin-3,  Myc-Cullin-4A,  and  Myc-Cullin-5  plasmids 
were obtained from Dr. J. Decaprio (Dana-Farber Cancer 
Institute, Boston, MA). Retroviral pSUPER short hairpin 
RNAs (shRNA) vectors against IKKα and IKKβ were 
obtained from Addgene.
Antibodies 
Anti-CYLD  (D1A10),  anti-IKKα,  anti-IKKα/β, 
anti-NFATc1,  anti-NF-kB1,  anti-NF-kB2,  anti-β-
TRCP1  (D13F10)  and  anti-Cullin  1  antibodies  were 
purchased from Cell Signaling Technology. Anti-c-Myc 
(9E10) and polyclonal anti-HA antibodies (Y-11) were 
purchased from Santa Cruz Biotechnology. Anti-Tubulin, 
anti-Vinculin,  polyclonal  and  monoclonal  anti-Flag 
antibodies, peroxidase-conjugated anti-mouse secondary 
antibody, peroxidase-conjugated anti-rabbit secondary 
antibody, anti-Flag agarose beads, and anti-HA agarose 
beads were purchased from Sigma-Aldrich. Monoclonal 
anti-HA antibody was purchased from Covance. Anti-
pSer436-CYLD  and  pSer432/436-CYLD  antibodies 
were developed in collaboration with Cell Signaling 
Technology.
Cell Transfections 
For transfection, 5×105 293T or HeLa cells were 
cultured in 6 cm dish and transfected with Lipofectamine 
(Invitrogen)  in  Opti-MEM  (Invitrogen)  according  to 
the  manufacturer’s  instruction.  Forty-eight  hours  after 
transfection, cells were lysed in EBC (50 mM Tris, pH 
8.0, 120 mM NaCl, and 0.5% NP-40) buffer supplemented 
with  protease  inhibitors  (Complete  Mini;  Roche)  and 
phosphatase inhibitors (phosphatase inhibitor cocktail set 
I and II; EMD). For half-life experiment, transfected cells 
were split into 60-mm tissue culture dishes 24 hours after 
transfection, and treated with 100 µg/ml cycloheximide 
(CHX; Sigma-Aldrich) next day. At indicated time points, 
cells were lysed for western blotting analysis. The lenti-
virus packaging procedures were described previously 
[45].
Immunoblots and Immunoprecipitation
Whole cell extracts were collected and the protein 
concentrations of the lysastes were measured with 
Bradford assay reagent (Bio-Rad Laboratories) on a DU-
800  spectrophotometer  (Beckman  Coulter).  Samples 
were resolved by SDS-PAGE and western blotted with 
the indicated antibodies. For immunoprecipitation, 
20 hours post transfection, cells were treated with 10 
µM  MG132  overnight,  and  then  were  harvested  for 
immunoprecipitation  procedures.  800  µg  of  protein 
lysastes were incubated with the appropriate antibody (1-2 
µg) overnight at 4 °C following by the addition of carrier 
beads. Immunocomplexes were washed five times with 
NETN buffer (20 mM Tris-Cl, pH 8.0, 100 mM NaCl, 1 
mM EDTA, and 0.5% NP-40), and then were resolved by 
SDS-PAGE and western blotted with indicated antibodies.
Osteoclastogenesis Assays
Bone marrow-derived macrophages (BMMs) were 
prepared as osteoclast precursors from 3- to 5-week-old 
male ddY mice. All procedures to prepare the precursor 
cells were conducted according to Public Health Service 
Policy on Humane Care and Use of Laboratory Animals 
and  the  Fukuoka  Dental  College  Institutional Animal 
Care and Use Committee (IACUC). Bone marrow cells 
obtained from the mouse tibia were suspended in 60-mm-
diameter dishes for 16 h in the presence of M-CSF (50 ng/
ml) in α-MEM containing 10% fetal bovine serum. Then, 
non-adherent cells were harvested and further cultured for 
2 days with M-CSF (50 ng/ml). The adherent cells, most 
of which expressed macrophage-specific antigens such as 
Mac-1, Moma-2, and F4/80, were used as BMMs. BMMs 
were cultured for 3 days with RANKL (50 ng/ml). The 
macrophage cell line RAW 264.7 cells were cultured for 
3 days with RANKL (20 ng/ml). Cultures were fixed with 
3.7% formaldehyde, and osteoclasts were detected by 
staining for tartrate-resistant acid phosphatase (TRAP). 
TRAP-positive  multinucleated  cells  containing  more 
than three nuclei were observed under a microscope and 
counted as differentiated osteoclasts.
Statistical Analysis
Data shown is representative of three independent 
experiments. All quantitative data were presented as the 
mean ± SD as indicated of at least three independent 
experiments  by  Student’s  t test for between group 
differences. The p < 0.05 was considered as statistically 
significant.
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